US1011371077 - Common Stock
BOSTON SCIENTIFIC CORP
NYSE:BSX (12/24/2024, 7:59:16 PM)
After market: 91.07 0 (0%)91.07
+1.21 (+1.35%)
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 48,000 full-time employees. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. The company also owns the transcarotid artery revascularization (TCAR) platform.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752
P: 15086834000
CEO: Michael F. Mahoney
Employees: 48000
Based on good technical signals, BOSTON SCIENTIFIC CORP is potentially setting up for a breakout.
/PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Boston Scientific (NYSE: BSX) Global Chief Medical Officer, Kenneth...
Interesting Technical Analysis finding for BOSTON SCIENTIFIC CORP (NYSE:BSX)
Here you can normally see the latest stock twits on BSX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: